Inhibition of STAT3 signaling may improve survival in those with H3.3G34R/V mutant gliomas, animal studies suggest.
While substantial strides have been made against some types of childhood cancers, high-grade gliomas still lack effective treatments.
Thirty to 60% of these pediatric brain tumors bear mutations in the gene H3F3A. This gene contains the encoded blueprint for histone H3.3, which plays an important role in the structure of chromatin. One of these mutations is known to scientists as H3.3G34R/V — meaning the amino acid glycine that’s normally found at position 34 has been replaced by either an arginine or a valine.
Now an international research team has found a small-molecule inhibitor that was able to suppress tumor growth in animal models of this glioma — offering new hope toward developing therapies for pediatric patients. Their findings appear in Science Translational Medicine.
“These tumors tend to occur in slightly older children than some of the more well-known types of childhood glioma — usually between the ages of 10 and 18,” said senior study author. “And the prospects remain quite dismal due to a lack of effective treatments.”
The team investigated epigenetic changes to the tumors — that is, changes that are not permanent mutations to the DNA itself, but which affect how cells access and read DNA sequences. Ultimately, they found alterations that led to increased secretion of a protein known as LIF, for leukemia inhibitory factor. LIF, in turn, activates the STAT3 signaling pathway, which has been implicated in a number of other types of cancer.
In mouse models of H3.3G34R/V glioma, a small-molecule inhibitor of STAT3 called WP1066 was shown to suppress tumor growth and greatly improve how long the mice survived.
The drug compound has the important property of being able to cross the blood-brain barrier, which is critical for developing brain cancer treatments, and is currently being tested in clinical trials for glioblastoma in adult patients, the author adds.
“Our goal is to move the compound into clinical trials for pediatric patients,” the author said.
https://www.science.org/doi/10.1126/scitranslmed.abf7860
Treating pediatric brain tumors harboring epigenetic mutation
- 987 views
- Added
Edited
Latest News
Immune cells identified as…
By newseditor
Posted 28 Mar
TB blood test which could d…
By newseditor
Posted 27 Mar
Propionate supplementation…
By newseditor
Posted 27 Mar
Role of human Kallistatin i…
By newseditor
Posted 26 Mar
Addressing both flu and COV…
By newseditor
Posted 26 Mar
Other Top Stories
Llama-derived antibodies provide universal flu protection
Read more
Gut bacteria may control movement
Read more
Immigration to the United States changes a person's microbiome
Read more
How gut microbiota recovers after antibiotic exposure
Read more
What triggers cell division?
Read more
Protocols
All-optical presynaptic pla…
By newseditor
Posted 23 Mar
Epigenomic tomography for p…
By newseditor
Posted 20 Mar
A mouse DRG genetic toolkit…
By newseditor
Posted 17 Mar
An optogenetic method for t…
By newseditor
Posted 13 Mar
Profiling native pulmonary…
By newseditor
Posted 08 Mar
Publications
BHLHE40/41 regulate microgl…
By newseditor
Posted 28 Mar
Balancing neuronal activity…
By newseditor
Posted 28 Mar
OSBP-mediated PI(4)P-choles…
By newseditor
Posted 28 Mar
Integrated plasma proteomic…
By newseditor
Posted 27 Mar
APP antisense oligonucleoti…
By newseditor
Posted 27 Mar
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar